Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioblastoma × amivantamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 19 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Salivary Gland Neoplasms 1 RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Non-small Cell Lung Cancers 1 Lung Neoplasms 1 Locally Recurrent Skin Squamous Cell Carcinoma 1 Head and Neck Neoplasms 1 Glioblastoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoma, Adenoid Cystic 1 Breast Neoplasms 1

Interventions

Temozolomide 362 Radiotherapy 181 Bevacizumab 142 Radiation 70 Magnetic Resonance Spectroscopy 60 Lomustine 43 pembrolizumab 37 Irinotecan 37 Carmustine 37 Surgical Procedures, Operative 34 Nivolumab 27 Carboplatin 25 Specimen Handling 23 Radiosurgery 23 Erlotinib Hydrochloride 23 Radiotherapy, Intensity-Modulated 20 Chemotherapy, Adjuvant 20 Aminolevulinic Acid 19 Cyclophosphamide 18 Drug Therapy 17 sargramostim 16 O(6)-benzylguanine 14 Radiotherapy, Conformal 13 Granulocyte-Macrophage Colony-Stimulating Factor 13 Everolimus 12 temsirolimus 11 Vorinostat 11 Sunitinib 11 Imatinib Mesylate 11 Etoposide 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06632236 2025-04-25

5G-EMERALD

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡